Exploring the Healthy Swiss Microbiome
SwissGut - A Longitudinal Cohort Study of the Healthy Human Faecal Microbiome in Switzerland
This study looks at how the gut bacteria of healthy Swiss people are influenced by their lifestyle and environment to see if it helps us understand diseases like colorectal cancer and inflammatory bowel diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 1 site (Bern) |
| Trial ID | NCT06191224 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between the gut microbiome, lifestyle factors, and the development of diseases such as colorectal cancer and inflammatory bowel diseases (IBD). It focuses on healthy Swiss individuals to provide control data for several related studies. The study aims to understand how environmental influences affect gut bacteria and their potential role in disease development. By analyzing the microbiome of healthy participants, the research seeks to identify differences in intestinal inflammation and bacterial strain behavior compared to individuals with IBD.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy individuals aged 18-90 years without any history of inflammatory bowel disease or colorectal cancer.
Not a fit: Patients with current gastrointestinal diseases or significant symptoms related to IBD may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of gut health and its implications for preventing inflammatory diseases.
How similar studies have performed: While this study is focused on healthy individuals, similar studies exploring the microbiome's role in health and disease have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent * Age 18-90 years * General ability to give consent for study inclusion, understand and follow study procedures * No current or past diagnosis of IBD or colorectal carcinoma * No current medical complaints typical for IBD or other severe intestinal diseases (e.g. Diarrhea, severe constipation, abdominal pain, blood in stool, weight loss). Minor symptoms, (not impairing daily activities) are permitted. * No other current relevant gastrointestinal disease or condition plausibly interfering with microbiota assessment according to the discretion of the study physician. Exclusion Criteria: * All patients with recent acute gastrointestinal disease (e.g., confirmed infectious diarrhea) within the last month or relevant intestinal symptoms (impairing daily activities). * Use of antibiotics within the last 3 months. * Current pouch or ileostomy/ colostomy. * Severe medical, surgical, or psychiatric comorbidities interfering with study procedure according to the judgement of the investigator (patients with comorbidities that would not interfere with the primary endpoints I-III but don't allow the assessment of HRV according to the judgement of the investigator (e.g. heart diseases) will be included in the study but the HRV will not be assessed). * Participation in an interfering clinical study.
Where this trial is running
Bern
- Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland — Bern, Switzerland (Recruiting)
Study contacts
- Principal investigator: Benjamin Misselwitz, MD — Inselspital, Bern University Hospital
- Study coordinator: Sebastian B. U. Jordi
- Email: research.2omrx@passfwd.com
- Phone: +41 31 664 33 63
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.